10x Genomics Slides as Rally Cools After Recent Product-Launch Surge

10x Genomics (TXG) is down 9.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is that investors are taking profits after a sharp run higher tied to enthusiasm around 10x Genomics’ recent Atera launch and its new Sentira analysis platform. There does not appear to be a major new negative company announcement driving the selloff today, so this looks more like a momentum reversal after a strong advance.

Details:

On September 29, 2026, the company announced the first commercial shipments of Atera, its new spatial biology platform, and described early demand as strong.

The same day, 10x Genomics introduced Sentira, a cloud-based analysis platform aimed at speeding interpretation of complex biological data, expanding its push beyond instruments and consumables.

In second-quarter 2026 results, management highlighted extraordinary customer response to Atera, while market trackers later showed multiple upward analyst price-target revisions following that product momentum.

Shares had already climbed sharply before today’s decline, with market data showing a powerful one-month and year-to-date run, which increases the odds of a pullback as traders lock in gains. This could be because expectations had become stretched after the recent rally.

Sources:

10x Genomics, SEC, Yahoo Finance, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TXG Insider Trading Activity

$TXG insiders have traded $TXG stock on the open market 39 times in the past 6 months. Of those trades, 0 have been purchases and 39 have been sales.

Here’s a breakdown of recent trading of $TXG stock by insiders over the last 6 months:

SERGE SAXONOV (Chief Executive Officer) has made 0 purchases and 16 sales selling 117,924 shares for an estimated $5,732,346.
ADAM TAICH (Chief Financial Officer) has made 0 purchases and 5 sales selling 78,652 shares for an estimated $4,446,341.
JOHN R STUELPNAGEL has made 0 purchases and 5 sales selling 40,000 shares for an estimated $2,390,127.
BENJAMIN J. HINDSON (See Remarks) has made 0 purchases and 2 sales selling 25,413 shares for an estimated $1,154,259.
SHEHNAAZ SULIMAN has made 0 purchases and 9 sales selling 13,653 shares for an estimated $791,901.
SARAH A. TEICHMANN has made 0 purchases and 2 sales selling 7,551 shares for an estimated $432,278.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive TXG Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$TXG Hedge Fund Activity

We have seen 188 institutional investors add shares of $TXG stock to their portfolio, and 165 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ added 4,375,792 shares (+2681.0%) to their portfolio in Q2 2026, for an estimated $167,767,865
MILLENNIUM MANAGEMENT LLC removed 1,951,581 shares (-94.4%) from their portfolio in Q2 2026, for an estimated $74,823,615
POINT72 ASSET MANAGEMENT, L.P. added 1,852,776 shares (+inf%) to their portfolio in Q2 2026, for an estimated $71,035,431
ARK INVESTMENT MANAGEMENT LLC removed 1,714,260 shares (-14.6%) from their portfolio in Q2 2026, for an estimated $65,724,728
CASDIN CAPITAL, LLC removed 1,225,000 shares (-53.8%) from their portfolio in Q2 2026, for an estimated $46,966,500
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,087,150 shares (+inf%) to their portfolio in Q2 2026, for an estimated $41,681,331
BALYASNY ASSET MANAGEMENT L.P. removed 989,522 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $37,938,273

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TXG Government Contracts

We have seen $3,952,499 of award payments to $TXG over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PROSTHETIST, PROSTHETIST TECHNICIAN, AND PROSTHETIST ASSISTANT IN THE DEPARTMENT OF SURGICAL SERVICES AND R...: $371,793
GENE EXPRESSION REAGENTS: $226,900

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$TXG Price Targets

Multiple analysts have issued price targets for $TXG recently. We have seen 8 analysts offer price targets for $TXG in the last 6 months, with a median target of $38.5.

Here are some recent targets:

Tejas Savant from Morgan Stanley set a target price of $37.0 on 07/09/2026
Patrick Donnelly from Citigroup set a target price of $45.0 on 07/08/2026
Eric Winmill from Scotiabank set a target price of $100.0 on 07/08/2026
David Westenberg from Piper Sandler set a target price of $42.0 on 07/01/2026
Luke Sergott from Barclays set a target price of $40.0 on 06/24/2026
Casey Woodring from JP Morgan set a target price of $20.0 on 05/12/2026
Kyle Mikson from Canaccord Genuity set a target price of $32.0 on 04/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.